ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 3,704 shares of the stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $171.00, for a total transaction of $633,384.00. Following the completion of the sale, the chief executive officer now directly owns 110,925 shares of the company’s stock, valued at approximately $18,968,175. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Vivek Jain also recently made the following trade(s):
- On Friday, July 7th, Vivek Jain sold 69,014 shares of ICU Medical stock. The stock was sold at an average price of $171.10, for a total transaction of $11,808,295.40.
- On Tuesday, July 11th, Vivek Jain sold 100,000 shares of ICU Medical stock. The stock was sold at an average price of $170.80, for a total transaction of $17,080,000.00.
ICU Medical, Inc. (NASDAQ:ICUI) traded down 0.61% during midday trading on Tuesday, reaching $171.55. The company’s stock had a trading volume of 116,162 shares. The firm has a market capitalization of $3.40 billion, a PE ratio of 30.49 and a beta of 0.37. The firm has a 50 day moving average price of $172.15 and a 200 day moving average price of $157.46. ICU Medical, Inc. has a 1-year low of $116.22 and a 1-year high of $176.50.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported $1.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $1.23. ICU Medical had a return on equity of 9.63% and a net margin of 18.76%. The firm had revenue of $247.74 million for the quarter, compared to analysts’ expectations of $237.12 million. During the same period in the prior year, the business posted $1.26 earnings per share. The business’s revenue was up 175.7% compared to the same quarter last year. On average, analysts predict that ICU Medical, Inc. will post $4.14 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/vivek-jain-sells-3704-shares-of-icu-medical-inc-icui-stock-updated-updated-updated/1195908.html.
A number of equities analysts have commented on ICUI shares. Zacks Investment Research downgraded shares of ICU Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 3rd. Sidoti downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a report on Tuesday, June 20th. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Finally, Roth Capital downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a report on Thursday, May 11th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $156.00.
A number of institutional investors have recently bought and sold shares of the company. Creative Planning raised its position in ICU Medical by 315.6% in the first quarter. Creative Planning now owns 665 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 505 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ICU Medical by 10.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock worth $122,000 after buying an additional 66 shares in the last quarter. Victory Capital Management Inc. raised its position in ICU Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 157 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in ICU Medical during the first quarter worth approximately $194,000. Finally, Parametrica Management Ltd acquired a new position in ICU Medical during the second quarter worth approximately $213,000. 77.85% of the stock is currently owned by institutional investors.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with our FREE daily email newsletter.